Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III double-blind randomized comparison of CMAB007 versus Xolair in chronic spontaneous urticaria
CTR20240900Phase 3Completed
- Sponsor
- Mabpharm Limited
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of omalizumab in chronic idiopathic urticaria (CIU), sponsored by Mabpharm Limited. Started Jul 2024; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on CTR20240900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240900.